General Information of Drug (ID: DM8TUPF)

Drug Name
Milrinone Drug Info
Synonyms
Corotrop; Corotrope; Milrila; Milrinona; Milrinonum; Primacor; Milrinona [Spanish]; Milrinonum [Latin]; M 4659; M1663; YM 018; MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER; Milrila (TN); PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER; Primacor (TN); WIN 47203-2; Win-47203; Milrinone [USAN:BAN:INN]; Win-47203-2; Milrinone (JAN/USAN/INN); 1,6-Dihydro-2-methyl-6-oxo(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4′-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-(3,4'-bipyridine)-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-3,4-bipyridine-5-carbonitrile; 1,6-Dihydro-2-methyl-6-oxo-[3,4'-bipyridine]-5-carbonitrile; 111GE027; 2-methyl-6-oxo-1,6-dihydro-3,4'-bipyridine-5-carbonitrile; 3-Cyano-6-methyl-5-(4-pyridyl)-2-pyridone; 6-Methyl-5-(4-pyridyl)-2-pyridone-3-carbonitrile; 6-methyl-2-oxo-5-pyridin-4-yl-1H-pyridine-3-carbonitrile
Indication
Disease Entry ICD 11 Status REF
Congestive heart failure BD10 Approved [1]
Cardiomyopathy BC43 Investigative [2]
Therapeutic Class
Cardiotonic Agents
Cross-matching ID
PubChem CID
4197
ChEBI ID
CHEBI:50693
CAS Number
CAS 78415-72-2
TTD Drug ID
DM8TUPF

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting Phosphodiesterase 3 (PDE3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cilostazol DMZMSCT Intermittent claudication BD40.00 Approved [3]
Oxtriphylline DMLHSE3 Cough MD12 Approved [3]
Ibudilast DM4LSPN Castleman's disease 4B2Y Approved [6]
Enoximone DMQVZJD Congestive heart failure BD10 Approved [7]
Olprinone DMWBQKU Heart failure BD10-BD13 Approved [8]
Inamrinone Lactate DMRMFP4 Cardiac disease BA00-BE2Z Approved [9]
Tofisopam DMTGNWU Hyperuricaemia 5C55.Y Phase 2 [10]
Tipelukast DMS9BDQ Asthma CA23 Phase 2 [11]
RPL-554 DMLD4VQ Allergic rhinitis CA08.0 Phase 2 [12]
Org-30029 DMDZ4R2 Heart failure BD10-BD13 Phase 2 [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By C-reactive protein (CRP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lidocaine DML4ZOT Anaesthesia 9A78.6 Approved [14]
Indinavir DM0T3YH Human immunodeficiency virus infection 1C62 Approved [15]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [16]
Quercetin DM3NC4M Obesity 5B81 Approved [17]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [18]
Acalabrutinib DM7GCVW leukaemia 2A60-2B33 Approved [19]
Penicillamine DM40EF6 Cystinuria 5C60.2 Approved [20]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [21]
Tibolone DM78XFG Anabolic metabolism 5C50-5C8Z Approved [22]
Testosterone DM7HUNW Hot flushes GA30 Approved [23]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ivacaftor DMZC1HS Cystic fibrosis CA25 Approved [24]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [25]
Rhucin DM3ADGP Erectile dysfunction HA01.1 Approved [5]
Quercetin DM3NC4M Obesity 5B81 Approved [26]
Miglustat DM5J64S Niemann-Pick disease type C Approved [27]
Glibenclamide DM8JXPZ Diabetic complication 5A2Y Approved [28]
Oxidized glutathione DM9EQC0 Breast cancer 2C60-2C65 Approved [29]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [29]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [30]
Flufenamic Acid DMC8VNH Dysmenorrhea GA34.3 Approved [31]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 3 (PDE3) TTZCG4L NOUNIPROTAC Modulator [3]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
C-reactive protein (CRP) OT0RFT8F CRP_HUMAN Gene/Protein Processing [4]
Cystic fibrosis transmembrane conductance regulator (CFTR) OT6B22QH CFTR_HUMAN Gene/Protein Processing [5]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5225).
2 Milrinone FDA Label
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 The efficacy of preemptive Milrinone or Amrinone therapy in patients undergoing coronary artery bypass grafting. Anesth Analg. 2002 Jan;94(1):22-30, table of contents. doi: 10.1097/00000539-200201000-00005.
5 Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells. Am J Respir Cell Mol Biol. 2003 Sep;29(3 Pt 1):410-8. doi: 10.1165/rcmb.2002-0247OC. Epub 2003 Apr 24.
6 Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond. Nat Rev Drug Discov. 2019 Oct;18(10):770-796.
7 In vitro and in vivo effects of the phosphodiesterase-III inhibitor enoximone on malignant hyperthermia-susceptible swine. Anesthesiology. 2003 Apr;98(4):944-9.
8 Olprinone: a phosphodiesterase III inhibitor with positive inotropic and vasodilator effects. Cardiovasc Drug Rev. 2002 Fall;20(3):163-74.
9 Effects of amrinone on hepatic ischemia-reperfusion injury in rats. J Hepatol. 2002 Jul;37(1):31-8.
10 The atypical anxiolytic drug, tofisopam, selectively blocks phosphodiesterase isoenzymes and is active in the mouse model of negative symptoms of psychosis. J Neural Transm (Vienna). 2010 Nov;117(11):1319-25.
11 Company report (MediciNova)
12 Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.Lancet Respir Med.2013 Nov;1(9):714-27.
13 Effects of the positive inotropic agent Org 30029 on developed force and aequorin light transients in intact canine ventricular myocardium. Circ Res. 1993 Mar;72(3):597-606.
14 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
15 C-Reactive protein levels over time and cardiovascular risk in HIV-infected individuals suppressed on an indinavir-based regimen: AIDS Clinical Trials Group 5056s. AIDS. 2004 Dec 3;18(18):2434-7.
16 Simvastatin combined with ramipril treatment in hypercholesterolemic patients. Hypertension. 2004 Aug;44(2):180-5. doi: 10.1161/01.HYP.0000133310.42762.25. Epub 2004 Jun 7.
17 The anti-inflammatory flavones quercetin and kaempferol cause inhibition of inducible nitric oxide synthase, cyclooxygenase-2 and reactive C-protein, and down-regulation of the nuclear factor kappaB pathway in Chang Liver cells. Eur J Pharmacol. 2007 Feb 28;557(2-3):221-9.
18 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
19 Inhibition of Bruton tyrosine kinase in patients with severe COVID-19. Sci Immunol. 2020 Jun 5;5(48):eabd0110. doi: 10.1126/sciimmunol.abd0110. Epub 2020 Jun 5.
20 The influence of alclofenac treatment on acute-phase proteins, plasma tryptophan, and erythrocyte sedimentation rate in patients with rheumatoid arthritis. Curr Med Res Opin. 1975;3(5):286-97. doi: 10.1185/03007997509114779.
21 Intractable insomnia after cessation of treatment with thalidomide. Gastroenterology. 2001 May;120(6):1567-8. doi: 10.1053/gast.2001.24495.
22 Effects of hormone treatment on hemostasis variables. Climacteric. 2007 Oct;10 Suppl 2:32-7. doi: 10.1080/13697130701598548.
23 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
24 Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010 Nov 18;363(21):1991-2003. doi: 10.1056/NEJMoa0909825.
25 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
26 Modulation of deltaF508 cystic fibrosis transmembrane regulator trafficking and function with 4-phenylbutyrate and flavonoids. Am J Respir Cell Mol Biol. 2004 Sep;31(3):351-7. doi: 10.1165/rcmb.2002-0086OC. Epub 2004 Jun 10.
27 Proteasome-dependent pharmacological rescue of cystic fibrosis transmembrane conductance regulator revealed by mutation of glycine 622. J Pharmacol Exp Ther. 2008 Apr;325(1):89-99. doi: 10.1124/jpet.107.134502. Epub 2008 Jan 29.
28 Comparative pharmacology of the activity of wild-type and G551D mutated CFTR chloride channel: effect of the benzimidazolone derivative NS004. J Membr Biol. 2003 Jul 15;194(2):109-17. doi: 10.1007/s00232-003-2030-z.
29 Reversible silencing of CFTR chloride channels by glutathionylation. J Gen Physiol. 2005 Feb;125(2):127-41. doi: 10.1085/jgp.200409115. Epub 2005 Jan 18.
30 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
31 Discovery of glycine hydrazide pore-occluding CFTR inhibitors: mechanism, structure-activity analysis, and in vivo efficacy. J Gen Physiol. 2004 Aug;124(2):125-37. doi: 10.1085/jgp.200409059.